Parenchyma Biotech Inc. has described aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of cancer and autoimmune disease.
Mablink Bioscience SAS., Université Claude Bernard Lyon 1 and Centre National de la Recherche Scientifique have patented antibody-drug conjugates consisting of antibodies covalently linked to therapeutic drugs through an enzyme-triggered self-immolative linker reported to be useful for the treatment of cancer.
Kirsten rat sarcoma viral oncogene (KRAS) is one of the GTPases from the RAS family activating signaling pathways that regulate cell functions. KRAS mutation of glycine to aspartate at position 12 (G12D) is a common mutation in pancreatic ductal adenocarcinoma, colorectal cancer, lung adenocarcinoma and other solid tumors. ASP-3082 is a proteolysis targeting chimera (PROTAC) under development by Astellas Pharma Inc. The company has presented the first in vitro and in vivo results of this new compound.
Transcode Therapeutics Inc. has reported positive preclinical results with its lead candidate, TTX-MC138, which targets microRNA-10b (miR-10b). The company evaluated the bioactivity of TTX-MC138 monotherapy in a murine model of pancreatic adenocarcinoma.
Novaccess Global Inc. has announced the approval of its application with the FDA for orphan drug designation for TLR-AD1, a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. The company’s therapeutic path involves a unique transformational process, which involves the addition of proprietary substances to create a cocktail for more personalized treatment that substantially increases clinical benefits for patients.
P-glycoprotein (P-gp) is a multidrug resistance (MDR)-associated protein, which is widely distributed in membranes of several cells including hepatocytes, renal proximal tubular cells and brain capillary endothelial cells. The overexpression of this drug efflux transporter protein is considered to play a key role in the development of MDR.
Diwali, the Festival of Light, marks different events depending on where it is celebrated. In some areas of India, it marks the return of Lord Rama to his birthplace of Ayodhya after defeating the demon Ravana. For Vivek Subbiah, associate professor at the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine of the MD Anderson Cancer Center, the story of how Rama defeated Ravana has parallels in drug discovery. Ravana had 10 heads, and when one was cut off, it grew back. Rama defeated Ravana by means of a magic arrow that entered through the demon’s navel.
Briefing documents related to the Oct. 28 meeting of the Oncologic Drugs Advisory Committee (ODAC) to deliberate over Y-mabs Therapeutics Inc.’s Omblastys (131I-omburtamab) took aim at the company’s ongoing, pivotal experiment called Study 101, data from which the company highlighted in early October.
The U.S. FDA cleared teclistamab from Janssen Pharmaceutical Cos. as the first bispecific antibody for treating patients with relapsed or refractory multiple myeloma (MM), joining other BCMA-targeted drugs, including an antibody-drug conjugate and CAR T therapies.
RSS
